Spain – Various medicinal products – suministro del medicamento REBLOZYL (principio activo LUSPATERCEPT 25 MG vial polvo
Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria awarded €234K to BRISTOL-MYERS SQUIBB, S.A for Construction & Public Works in June 2024 — one of 94 awards this buyer has made, below its typical award size.
Winning supplier
BRISTOL-MYERS SQUIBB, S.AContract description
Spain – Various medicinal products – suministro del medicamento REBLOZYL (principio activo LUSPATERCEPT 25 MG vial polvo subcutanea, LUSPATERCEPT 75 MG vial polvo subcutanea) Y ZEPOSIA (principio activo OZANIMOD 0,92 MG capsula oral), con destino Servicio de Farmacia del Hospital Universitario Nuestra Señora de Candelaria
Related awards · Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria
94 awardsThe buyer's full award list ranked by value, with the winning supplier, date and sector on every row — plus CSV / API export.
- ocds-ted-354025-2025WERFEN ESPAÑA, S.A.U.€652K02 Jun 2025 Construction
- ocds-ted-696051-2024KERN PHARMA, S.L.€561K15 Nov 2024 Construction
- ocds-ted-693178-2024Roche Farma, S.A.€553K14 Nov 2024 Construction
Other wins · BRISTOL-MYERS SQUIBB, S.A
65 winsThe supplier's complete win history across every buyer it sells to — not just the handful shown here.
- ocds-ted-431930-2026OSAKIDETZA - Servicio Vasco de Salud - Organización Central€64.7M25 Jun 2026 Construction
- ocds-ted-680665-2024OSAKIDETZA - Servicio Vasco de Salud - Organización Central€18.3M08 Nov 2024 Construction
- ocds-ted-435978-2026-6SERGAS. Servicio Gallego de Salud.€13.0M25 Jun 2026 Construction
Premium · full dataset
See the full award context.
Competing bids, award margins and every related contract for Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria and BRISTOL-MYERS SQUIBB, S.A — one subscription unlocks everything.
Sign Up Free →Free account · cancel anytime · 14-day money-back